OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Neurology is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)

Article	Citations
Transmembrane protein interacts with α-synuclein to confer risk of PD	574
Lymphatic propagation of α-synuclein	365
Promising results for antisense RNA therapy in mouse models of diffuse midline glioma	354
Brain stimulation aids walking after spinal injury	324
ANA2025 marks important milestones for the ANA and NINDS	263
Refining oxytocin therapy for autism: context is key	260
Reply to ‘Perils and pitfalls of near-death experience research’	249
Neural cell state shifts and fate loss in ageing and age-related diseases	248
Ventricular enlargement caused by aducanumab	235
Microglia, spreaders of Aβ seeds	234
Epstein–Barr virus as a leading cause of multiple sclerosis: mechanisms and implications	232
Deciphering nociplastic pain: clinical features, risk factors and potential mechanisms	230
Global synergistic actions to improve brain health for human development	226
NODDI reveals brain microstructural changes in multiple sclerosis	216
CD11c+ macrophages mediate brain-to-gut α-synuclein trafficking	211
Disease-specific modifications of tau protein	172
Continuous levodopa production by an artificial enzyme	168
TREM2 mediates phagocytosis in glioblastoma	157
Study reveals new ALS risk genes	146
SEQUINS — a new initiative to address disparities in neurology	145
Nir Giladi (1955–2024)	144
Spinal muscular atrophy treatment in utero	142
Rapidly progressive dementias — leukodystrophies as a potentially treatable cause	141
The Digitized Memory Clinic	117
Mitochondrial DNA instability in Huntington disease	117

Imperatives and co-benefits of research into climate change and neurological disease	113
The impact of rare genetic variants on Alzheimer disease	113
The role of the gut microbiota in multiple sclerosis	110
Psychosis-causing lesions mapped to a hippocampal circuit	108
Neuroinflammation predicts cognitive decline in FTD	107
Implications of AD plasma and PET biomarker discordance	107
Ultrasound lets gene therapy into the brain	105
Menopause influences tau pathology	101
Role for endogenous retrovirus in FTD	100
Brain volume is associated with cognition in MS	99
Amyloid plaques: hotspots for microglial turnover	98
Challenges of combining multimodal data in assessment of people with traumatic brain injury	91
MRI-based deep learning for TLE diagnosis	91
Diversity, equity and inclusion in neurology	90
Gene therapy for seizures in focal cortical dysplasia	88
Author Correction: Viral pathogens increase risk of neurodegenerative disease	87
Precision neuroimmunology in multiple sclerosis — the horizon is near	80
First trials test targeting of α-synuclein for Parkinson disease	80
Parkinson disease pathology can originate in the kidney	78
Neurological care for LGBT+ people	74
The challenges of anti-tau therapeutics in Alzheimer disease	74
Management of freezing of gait — mechanism-based practical recommendations	73
The noradrenergic subtype of Parkinson disease: from animal models to clinical practice	72
Implementation of the 2024 revision of the McDonald criteria for multiple sclerosis	71
Blood GFAP as an emerging biomarker in brain and spinal cord disorders	70
Neurosteroids alleviate seizures in rats	65
α-Synuclein pathology as a target in neurodegenerative diseases	65
Food is brain medicine — relevance and translation to neurology	65
Glymphatic dysfunction in PD clinical progression	62
Addressing disparities in neurology by building the workforce in LMICs	61
A new biological classification for Parkinson disease	61
Ultrasound ablation treatment for PD	61
Evidence for altered astrocyte function in Duchenne muscular dystrophy	61
Thalamic inflammation — a therapeutic target for brain injury?	57
Exosomal microRNA is promising biomarker in PD	56
Author Correction: Why won’t it stop? The dynamics of benzodiazepine resistance in status epilepticus	55
Coeliac disease as a model for understanding multiple sclerosis	55
New IDEAS about amyloid, race and dementia disparities	55
Amyloid-lowering immunotherapies for Alzheimer disease: current status and future directions	54
Why won’t it stop? The dynamics of benzodiazepine resistance in status epilepticus	53
Post-COVID dysautonomias: what we know and (mainly) what we don’t know	51
Spinal cord stimulation for the treatment of chronic pain	51
Knowing the enemy: strategic targeting of complement to treat Alzheimer disease	50
Is Alzheimer disease a disease?	47
From the prodromal stage of multiple sclerosis to disease prevention	47
The role of glial cells in multiple sclerosis disease progression	46
The global and regional burden of diabetic peripheral neuropathy	45
X-chromosome variants and PD in Latin America	45
Oligomeric tau could spread through synapses in AD	45
Synaptic degeneration in Alzheimer disease	45

Genetic susceptibility determines Epstein–Barr-virus-associated risk of multiple sclerosis	44
Continuing evolution of migraine-specific therapies — targeting migraine with precision and persistence	44
Neurofilament light chain induces neuroinflammation	44
Hypothyroidism is associated with dementia risk	44
Neurology in 2025 — reflections from Africa	43
Limbic-predominant age-related TDP43 encephalopathy (LATE) neuropathological change in neurodegenerative diseases	43
Peripheral nervous system immune-related adverse events due to checkpoint inhibition	42
The inter-relationship between delirium and dementia: the importance of delirium prevention	41
Global epidemiology of migraine and its implications for public health and health policy	41
Moving towards meaningful patient and public engagement	40
α-Synuclein seeds in amyotrophic lateral sclerosis	40
Risk locus for paediatric astrocytoma identified	40
T cells implicate Epstein–Barr virus in multiple sclerosis pathogenesis	40
Dual function of biomolecular condensates	40
Huntington disease-like 2: insight into neurodegeneration from an African disease	39
Prognostic plasma biomarkers for spinal cord injury	38
Multi-ancestry GWAS identifies 16 novel Alzheimer disease risk loci	37
Change in stroke outcomes over 20 years	36
Origins and immunopathogenesis of autoimmune central nervous system disorders	35
Safety and efficacy of COVID-19 vaccines in people with neurological disorders	35
Impaired glymphatic drainage links amyloid and tau to cognitive dysfunction	35
Plasma extracellular vesicle biomarkers for frontotemporal dementia and related disorders	34
The role of astrocytic α7 nicotinic acetylcholine receptors in Alzheimer disease	33
Facioscapulohumeral muscular dystrophy: the road to targeted therapies	31
New developments in guidelines for brain death/death by neurological criteria	29
Insights from 25 years of onabotulinumtoxinA in migraine — mechanisms and management	28
CAR T cells offer hope in glioblastoma	28
Neurology in 2025 — reflections from the USA	27
Reactive astrocyte biomarkers mirror Alzheimer disease pathology	27
The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology	26
Inflammasomes in neurological disorders — mechanisms and therapeutic potential	26
High rate of epilepsy in young individuals who died with COVID-19	25
John Q. Trojanowski	24
Twin study probes non-heritable immune aspects of multiple sclerosis	24
Does antiherpetic antiviral therapy reduce the risk of dementia?	24
Serum NfL as an MS biomarker	24
Aberrant protein networks in Alzheimer disease	23
ALS pathogenesis linked to actin barrier collapse	23
BCAS1+ oligodendrocytes aid remyelination in MS	22
AI aces diagnosis of chronic ataxias	21
Author Correction: The complex aetiology of cerebral palsy	20
Charting brain development across the human lifespan	20
Pharmacological rehabilitation for stroke	20
Antisense oligonucleotide shows potential in Charcot–Marie–Tooth disease	20
AI and protein structure and function in neurological disease: relevance to disease management	19
The murky waters of sex differences in post-stroke cognitive impairment	19
Addressing disparities in the global epidemiology of stroke	18
Neuroprognostication: a conceptual framework	18
Pathogenetic mechanisms and treatment targets in cerebral malaria	17
Alzheimer disease in African American individuals: increased incidence or not enough data?	16
Genome-wide analysis furthers decoding of Alzheimer disease genetics	16
Clocking the age of Parkinson disease onset	15
Molecular biomarkers for vascular cognitive impairment and dementia	15
Effects of diet on MS onset and course	15
Addressing racial inequities in neuropsychological assessment requires international prescriptive standards, not demographically adjusted norms	14
Nusinersen treatment response markers	14
Predictive tools in psychosis: what is ‘good enough’?	14
Altered muscle cholesterol transport in ALS	14
From adaptive deep brain stimulation to adaptive circuit targeting	13
Nanoprobe for blood–brain barrier changes	13
Advancing multiple sclerosis management in older adults	13
Sex and gender in neurodevelopmental conditions	12
Mechanistic insights into the interaction between epilepsy and sleep	12
Multidimensional MRI detects astrogliosis	12
Disease-modifying therapies for Parkinson disease: lessons from multiple sclerosis	12
Markers help to predict dementia with Lewy bodies	12
Alzheimer disease seen through the lens of sex and gender	12
Advances in the therapeutic algorithm for myasthenia gravis	11
Parkinson disease pathology in inflammatory bowel disease	11
Shared glial pathology in HD and schizophrenia	11